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 ABSTRACT 
 The study objective was to compare the efficacy of 
3 commercial dry cow mastitis formulations regarding 
quarter-level prevalence of intramammary infections 
(IMI) postcalving, cure of preexisting infections over 
the dry period, prevention of new infections during the 
dry period, and risk for a clinical mastitis case between 
calving and 100 d in milk (DIM). A total of 1,091 cows 
(4,364 quarters) from 6 commercial dairy herds in 4 
different states (California, Iowa, Minnesota, and Wis-
consin) were enrolled and randomized to 1 of the 3 
treatments at dry-off: Quartermaster (QT; 1,000,000 
IU of procaine penicillin G and 1 g of dihydrostrepto-
mycin; Pfizer Animal Health, New York, NY), Spec-
tramast DC (SP; 500 mg of ceftiofur hydrochloride; 
Pfizer Animal Health), or ToMorrow Dry Cow (TM; 
300 mg of cephapirin benzathine; Boehringer Ingelheim 
Vetmedica Inc., St. Joseph, MO). Quarter milk samples 
were collected for routine bacteriological culture before 
dry cow therapy treatment at dry-off, 0 to 6 DIM, and 
7 to 13 DIM and an on-farm record-keeping system 
was used to retrieve data on clinical mastitis cases. 
Noninferiority analysis was used to evaluate the effect 
of treatment on the primary outcome, risk for a bac-
teriological cure during the dry period. Multivariable 
logistic regression techniques were used to describe the 
effect of treatment on risk for presence of IMI postcalv-
ing and risk of a new IMI during the dry period. Cox 
proportional hazards regression was used to describe 
the effect of treatment on the risk and time for quarters 
to experience an episode of clinical mastitis between 
calving and 100 DIM. The overall crude quarter-level 
prevalence of infection at dry-off was 19.2%. The most 
common pathogen isolated from milk samples at dry-
off was coagulase-negative Staphylococcus, followed by 
Aerococcus spp. and other Streptococcus spp. Noninferi-
ority analysis showed no effect of treatment on risk for 
a cure between dry-off and calving [least squares means 
(LSM): QT = 93.3%, SP = 92.6%, and TM = 94.0%] 
and secondary analysis showed no effect of treatment 
on risk for presence of an IMI at 0 to 6 DIM (LSM: 
QT = 16.5%, SP = 14.1%, and TM = 16.0%), risk for 
development of a new IMI between dry-off and 0 to 
6 DIM (LSM: QT = 14.8%, SP = 12.3%, and TM = 
14.2%), or risk of experiencing a clinical mastitis event 
between calving and 100 DIM (LSM: QT = 5.3%, SP 
= 3.8%, and TM = 4.1%). In conclusion, no difference 
was observed in efficacy among the 3 products evalu-
ated when assessing the aforementioned quarter-level 
outcomes. 
 Key words:   dry cow mastitis ,  dry cow therapy , 
 quarter-level outcome 
 INTRODUCTION 
 The dry period corresponds to a crucial period when 
lactating cows go through physiological changes to pre-
pare the mammary gland for the next lactation. The 
importance of mastitis during the dry period has been 
explored by several authors (Oliver and Mitchell, 1983; 
Eberhart, 1986; Erskine, 2001). Persistence of preexist-
ing IMI through the dry period and development of 
new IMI (NIMI) during the dry period are 2 impor-
tant factors that increase the risk for manifestation of 
clinical mastitis in the next lactation. Estimates of dry 
cow mastitis incidence rates vary among studies, in 
part due to differences in definitions of IMI, regional 
differences, and herd differences. North American stud-
ies have estimated the proportion of quarters develop-
ing an NIMI during the dry period to range between 8 
and 25% (Eberhart, 1986; Godden et al., 2003; Cook et 
al., 2005). The majority of new infections are subclini-
cal during the dry period, but can flare up as clinical 
mastitis, usually in early lactation (Green et al., 2002). 
It has been estimated that 55% of environmental infec-
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tions established early in the dry period persist into the 
next lactation and can possibly cause clinical flare-ups 
(Todhunter et al., 1995), and that 52% of all clinical 
coliform mastitis cases occurring in the first 100 d of 
lactation may originate during the previous dry period 
(Bradley and Green, 2000). Smith et al. (1985) reported 
that the risk for NIMI from environmental pathogens 
can be 10 times higher during the dry period than dur-
ing the lactation period.
Blanket dry cow therapy (DCT), which refers to the 
intramammary infusion of all quarters of all cows at 
dry-off with a long-acting antibiotic, is a procedure rec-
ommended by the National Mastitis Council (NMC) 
as mastitis control practice, both for the purpose of 
curing existing subclinical infections and preventing 
new infections that could be acquired during the early 
dry period. North American studies estimate the pro-
portion of quarters infected subclinically at dry-off to 
vary between 13 and 35% (Oliver and Mitchell, 1983; 
Godden et al., 2003; Pantoja et al., 2009). Advantages 
of using DCT include avoidance of milk discard during 
the lactation period, use of larger doses of antibiotic 
(so that concentrations can stay above MIC for longer 
periods of time), and reduction in risk for antibiotic 
residues in saleable milk. It has been estimated that 
72.3% of the US dairy operations use blanket DCT, 
which corresponds to 81.7% of US dairy cows (USDA-
NAHMS, 2008).
According to the 2013 “Milk and Dairy Beef Drug 
Residue Prevention” manual (National Milk Produc-
ers Federation, 2013) 7 commercial dry cow mastitis 
products are currently approved by the Food and Drug 
Administration for use in US dairy herds. Milk and 
meat withhold period, dry period length, claimed spec-
trum of action, and cost for these products vary con-
siderably. Three commonly used dry cow products in 
the United States include Quartermaster (QT; Pfizer 
Animal Health, New York, NY), Spectramast DC (SP; 
Pfizer Animal Health), and ToMorrow Dry Cow (TM; 
Boehringer Ingelheim Vetmedica Inc., St. Joseph, MO). 
Quartermaster is composed of 1,000,000 IU of procaine 
penicillin G and 1 g of dihydrostreptomycin. It is la-
beled to reduce the frequency of existing infections and 
prevent new infections caused by Staphylococcus aureus. 
Milk and meat withholding times are 96 h postcalving, 
and 60 d postinfusion, respectively. The dry period 
length is required to be at least 42 d. Spectramast DC 
is composed of 500 mg of ceftiofur hydrochloride and 
labeled for subclinical mastitis associated with Staph. 
aureus, Streptococcus dysgalactiae, and Streptococcus 
uberis. It has no milk withholding time and the meat 
withdrawal period is 16 d postinfusion for this prod-
uct. The required dry period length is 30 d. Finally, 
TM contains 300 mg of cephapirin and is labeled to 
be effective on the treatment of mastitis caused by 
Streptococcus agalactiae and Staph. aureus, including 
penicillin-resistant strains. Milk and meat withholding 
times are 3 d after calving and 42 d after treatment, 
respectively, and the required dry period length is 30 d.
The efficacy of commercial DCT products compared 
with negative controls (untreated quarters) has been 
previously demonstrated for each of these products 
to receive Food and Drug Administration approval. 
However, studies comparing efficacy among available 
DCT products in field conditions in North American 
dairy herds have been previously lacking. Hallberg et 
al. (2006) conducted a study to evaluate the efficacy 
of ceftiofur hydrochloride for the treatment of existing 
IMI at dry-off and prevention of NIMI during the dry 
period using a negative control and a positive control 
(cephapirin benzathine), but that study was not de-
signed to compare efficacy between the 2 antimicrobial 
formulations used, nor did the authors complete and 
report statistical analysis comparing the 2 antimicro-
bial treatments. Furthermore, that study only enrolled 
cows with an elevated SCC (>400,000 cells/ mL), and 
so results may not be generalizable to commercial dairy 
herds wherein blanket DCT is usually applied to all 
cows. A recent study conducted in Florida compared 
treatment with SP with treatment with QT at the 
cow level, but the authors did not report quarter-level 
outcomes such as risk for new IMI or risk for cure of 
preexisting IMI (Pinedo et al., 2012). The compara-
tive efficacy of available DCT formulations deserves to 
be investigated so that producers can make informed 
science-based decisions when selecting DCT products 
for use in their herds. The ultimate goal of the current 
noninferiority multi-herd, multi-state study is to pro-
mote judicious drug use while providing producers with 
needed information to guide the selection of efficacious 
DCT products, thus promoting cow health and welfare, 
as well as economic sustainability of the dairy farm.
The study objective was to compare the efficacy of 3 
commercial DCT products as measured by quarter-level 
risk for presence of an IMI postcalving, risk for cure of 
an IMI during the dry period, risk for development of 
NIMI over the dry period, and risk for experiencing a 
clinical mastitis event between calving and 100 DIM. 
The hypothesis tested was that quarters infused with 
cephapirin benzathine at the time of dry-off would have 
a noninferior proportion of quarters cured from preex-
isting IMI, and would have similar prevalence of IMI 
postcalving, incidence of NIMI over the dry period, and 
incidence of clinical mastitis from calving to 100 DIM 
compared with quarters infused with either ceftiofur 
hydrochloride or penicillin/dihydrostreptomycin.
Journal of Dairy Science Vol. 96 No. 7, 2013
RANDOMIZED STUDY COMPARING DRY COW THERAPIES 4421
MATERIALS AND METHODS
Herd Selection
A noninferiority randomized clinical trial was con-
ducted under Institutional Animal Care and Use 
Committee (IACUC) approval from each participating 
University between February 2011 and November 2011 
in 6 commercial dairy herds located in California (n = 
2), Iowa (n = 1), Minnesota (n = 1), and Wisconsin (n 
= 2). Herds were located within a reasonable driving 
distance from the collaborating institution. Inclusion 
criteria for study herds included to be on a regular 
DHIA testing program and comply with the study 
protocol. This convenience sample of herds averaged 
2,230 lactating cows (range of 1,050 to 3,600), with an 
average bulk tank SCC of 242,170 cells/ mL (range of 
148,000 to 330,000 cells/ mL), and a rolling herd aver-
age of 12,360 kg (range of 10,610 to 13,550 kg; Table 1). 
Bulk samples were negative on culture for Mycoplasma 
spp. for all 6 herds before initiating the study. All 
herds routinely used an internal teat sealant at dry off 
(Orbeseal; Pfizer Animal Health), commercial coliform 
mastitis vaccines, and blanket DCT.
Cow Enrollment
To be eligible for enrollment, cows had to be in good 
general health, have 4 functioning quarters, have not 
received parenteral or intramammary treatment with 
an antibacterial or antiinflammatory medication during 
a 30-d period immediately before dry off and show no 
clinical signs of clinical mastitis on the day of dry-off. 
All study enrollment and sampling activities were con-
ducted by the authors or University technicians who 
visited the herd weekly. Cows due to be dried off were 
brought into the parlor for their last milking and rou-
tine DCT. Cow identification numbers were previously 
assessed and animals were checked for previous medica-
tion. Animals were identified while entering the parlor 
and visually inspected for clinical signs of illness such 
as very low BCS (<2.0) or moderate to severe lameness. 
The udder and milk were inspected for signs of clinical 
mastitis. Eligible cows were randomly allocated to treat 
all 4 quarters with 1 of the 3 treatments (QT, SP, or 
TM) according to a previously prepared randomized 
spreadsheet created in Excel software (2010; Microsoft 
Corp., Santa Rosa, CA). Randomization was blocked 
within farms on each day of enrollment.
Routine parlor udder preparation was performed by 
the farm personnel while study investigators recorded 
teat end and udder hygiene scores. Although the 
type of predip used and sequence of predipping and 
forestripping was not identical among all herds, the 
general process involved predipping, forestripping, and 
redipping, leaving the dip on for at least 45 s of contact 
time, and then wiping teat barrel and teat end dry 
with a clean cloth towel. Teat end scores ranged from 
1 (no teat end crack or callosity) to 4 (cracked teat 
end; Falkenberg et al., 2003) and udder hygiene scores 
ranged from 1 (clean) to 4 (dirty; Schreiner and Ruegg, 
2003). Following routine udder preparation, sample 
collectors cleaned and disinfected the teat ends using 
gauze squares soaked in 70% isopropyl alcohol. Three 
strippings of fore milk were discarded and duplicate 
quarter samples were aseptically collected into sterile 
milk vials previously identified with herd, cow number, 
quarter, and date. After sample collection (sample 1, 
S1), the routine final milking procedure took place and 
milk sample vials were placed into a chilled cooler on 
ice. Immediately following the final milking, all 4 quar-
ters were again scrubbed with alcohol-soaked gauze, 
the assigned treatment was infused into each of the 
4 quarters, and finally the internal teat sealant was 
infused. All cows were postdipped and moved to their 
respective dry cow facilities, where usual farm dry cow 
husbandry and management practices were undertaken.
Postcalving Sampling and Follow-Up
Investigators visited the herds once per week and 
postcalving duplicate quarter milk samples were col-
lected at 2 different time periods: 0 to 6 DIM (sample 
Table 1. Herd descriptors 
Item Herd A Herd B Herd C Herd D Herd E Herd F
State Wisconsin Wisconsin Minnesota Iowa California California
RHA1 (kg) 13,170 12,690 13,550 12,310 10,610 11,790
SCC2 (cells/mL) 284,000 275,000 236,000 148,000 330,000 180,000
Size (no. of lactating cows) 1,550 1,050 1,650 3,030 2,500 3,600
Housing during dry period Freestall, pasture Freestall Freestall Open lot Open lot Freestall, open lot
Bedding during dry period Sand Biosolids Sand Corn stalk Biosolids Biosolids
Housing during lactation Freestall Freestall Freestall Freestall Open lot Freestall
Bedding during lactation Sand Biosolids Sand Sand Biosolids Biosolids
1Milk production annual rolling herd average (RHA).
2Bulk tank milk average SCC.
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2, S2) and 7 to 13 DIM (sample 3, S3). The procedure 
for sample collection was the same as previously de-
scribed for S1 collected at dry-off. All clinical mastitis 
events occurring in the first 100 DIM were recorded by 
farm staff using an on-farm electronic record-keeping 
system (DairyComp305; Valley Agricultural Software, 
Tulare, CA) and farm personnel were asked to collect 
and freeze an aseptic milk sample from the affected 
quarter at time of detection of a clinical case. Clini-
cal mastitis was defined as visibly abnormal milk ac-
companied or not by changes in the quarter. Samples 
were kept frozen (−20°C) at the farm until the next 
investigator’s visit. DairyComp305 software was used 
to capture electronic DHIA records for all study cows 
throughout the 100-DIM observation period to provide 
test-day measures of previous linear score and previous 
milk production, clinical mastitis events, and death and 
culling events. The effect of treatment on long-term 
cow-level outcomes will be reported upon in a compan-
ion manuscript.
Laboratory Methods
Milk samples collected on farms were placed on ice 
and transported back to the local participating labo-
ratory (Laboratory for Udder Health, St Paul, MN; 
Veterinary Diagnostic Laboratory, Ames, IA; or Dairy 
Food Safety Laboratory, Tulare, CA), where they were 
immediately frozen at −20°C until they could undergo 
bacterial culture. Bacteriological milk culture proce-
dures were standardized as much as possible among 
the 3 participating laboratories and followed published 
procedures recognized by the NMC for bovine mastitis 
(NMC, 1999). Only one of each pair of duplicate quar-
ter samples was routinely selected for microbial culture. 
The second paired sample was kept frozen in reserve 
and only cultured in cases where the first sample was 
contaminated.
Samples to be cultured were thawed to room temper-
ature and 0.01 mL of milk was plated into MacConkey 
agar and either Factor agar (for those samples submit-
ted to the Minnesota laboratory) or blood agar (for 
samples submitted to California or Iowa laboratories) 
using calibrated loops (note: Factor agar is routinely 
used at the Laboratory for Udder Health from the 
University of Minnesota, St. Paul, for selective growth 
of gram-positive organisms; University of Minnesota 
Laboratory for Udder Health, 2013). Inoculated plates 
were incubated at 37°C for 48 h and then observed 
for bacterial growth. For plates with bacterial growth, 
the number of colonies was recorded for each species 
isolated, and colonies were reisolated on blood agar for 
further characterization. Colony morphology, hemolysis 
pattern, and Gram staining results were described.
Further characterization of gram-positive organ-
isms involved the catalase test reaction to differentiate 
Staphylococcus and Streptococcus species, and then co-
agulase testing. Organisms that were catalase positive 
and coagulase negative were reported as CNS, whereas 
catalase- and coagulase-positive organisms were re-
ported as Staph. aureus. Catalase-negative organisms 
had their identity confirmed by the API Streptococcus 
identification system (bioMérieux Vitek Inc., Hazel-
wood, MO). Pathogens reported as other Streptococ-
cus spp. corresponded to subspecies of Streptococcus 
that are less commonly reported in the literature or 
to pathogens that could not be identified by the API 
Streptococcus system. Gram-positive organisms that 
were in very low prevalence and pathogens that grew 
in Factor but not in MacConkey agar and could not be 
identified were reported as “other gram positives.”
Further characterization of gram-negative organisms 
involved motility testing and then testing with the 
API20E system (bioMérieux Vitek Inc.). Organisms 
that could not be identified by the API system were 
reported as “other gram negatives.” Finally, nonbacte-
rial pathogens such as yeast were reported as “others.”
If 3 or more pathogens were present in a single 
sample, it was considered contamination and the du-
plicate sample was cultured. If the duplicate sample 
also yielded 3 or more bacterial pathogens, the quarter 
sample was reported as contaminated. Blinding of the 
sample collectors or producer at the time of treatment 
was not possible. However, laboratory personnel were 
blinded to treatment.
Definitions
Presence of an IMI. An IMI was defined as 1 or 
more colonies isolated from a 0.01-mL milk sample for 
all pathogens except for CNS and Bacillus spp. For 
CNS, 2 or more colonies isolated from a 0.01-mL milk 
sample were needed to establish presence of an IMI 
(Dohoo et al., 2011). For Bacillus spp., an IMI was 
defined as 5 or more colonies isolated from a 0.01-mL 
milk sample. Because no peer-reviewed studies exist 
determining a cutoff point for the latter organism, the 
definition for IMI for Bacillus spp. was established 
during an informal discussion among mastitis experts 
(chaired by B. Owens, Louisiana State University Ag-
ricultural Center, Hill Farm Research Station, Homer) 
conducted during the 2011 Mastitis Research Workers’ 
Conference (Nov. 1, 2011, Chicago, IL). A single IMI 
was defined as the presence of only 1 type of pathogen 
in the sample, whereas mixed infections corresponded 
to the presence of 2 different bacterial species.
Bacteriological Cure. A cure was defined as the 
failure to culture 1 or 2 of the pathogens originally 
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present at the dry-off sample (Godden et al., 2003) in 
both postcalving samples (S2 and S3). Quarters with 
contaminated or missing samples were not included in 
the analysis.
New IMI. An NIMI was defined as quarters from 
which no pathogens were recovered at dry-off (S1) but 
growth was later detected in the first postcalving sam-
ple (S2) or a different (new) pathogen was recovered 
at S2 compared with S1. Quarters that had 1 or both 
samples contaminated or missing were not included in 
the analysis. It was possible for the same quarter to 
experience both a cure and an NIMI.
Statistical Analysis
For the a priori sample size calculation, the primary 
outcome considered was risk for a cure. The minimum 
difference in cure rate to declare noninferiority of TM 
compared with SP or QT was prestated at 10%. To 
demonstrate noninferiority, a total of 339 cows (1,356 
quarters) per group were estimated to be required (as-
suming α = 0.025 and β = 0.2), along with 10% losses 
to follow-up and 30% of the quarters infected at dry-off 
and, therefore, at risk for a cure (noninferiority tests for 
2 proportions; Pass 2008; NCSS LLC, Kaysville, UT).
All statistical analyses were conducted using the 
intent-to-treat approach at the quarter level in SAS 
(version 9.2: SAS Institute Inc., Cary, NC). Initially de-
scriptive statistics and plots were generated for explor-
atory data analysis. Basic diagnostic techniques were 
used to evaluate normality and presence of outliers. 
Characteristics of cows and quarters assigned to the 3 
treatment groups were initially compared at baseline 
using the chi-squared test and ANOVA.
The effect of treatment on binary outcomes such as 
risk for presence of IMI, cure, and NIMI were estimated 
using multivariable logistic regression (generalized lin-
ear mixed model) using PROC GLIMMIX, with region 
included as a fixed effect and herd and cow included as 
random effects in the model to account for the cluster-
ing effects of herds within regions (3 different partici-
pating laboratories), cows within herds, and quarters 
within cows.
Covariates offered to the model included DCT 
treatment group (forced), cow parity, previous lacta-
tion linear score (LS), previous lactation total milk 
production (kg), dry period length (d), teat end score 
at dry-off and postcalving, and udder hygiene score at 
dry-off and postcalving. The variables previous lacta-
tion LS, previous lactation total milk production, and 
dry period length were offered as continuous variables. 
Udder hygiene score was offered as a categorical vari-
able in 4 levels and cow parity was dichotomized in 2 
categories: second parity and third-or-greater parities. 
Teat end score was initially captured in 4 categories but 
2 categories were considered in the model: categories 1 
and 2 and categories 3 and 4, for the reason that rela-
tively few teat ends scored 4. Univariate analysis was 
initially conducted between each of the aforementioned 
variables and the dependent variable of interest, and 
variables significant at P < 0.2 were then carried for-
ward to offer to the full model. Nonsignificant variables 
were then removed one at a time using a backward 
stepwise approach, with final significance declared at 
P < 0.05. First-order interactions between DCT treat-
ment group and other remaining main effects were 
tested and included in the model if significant. Models 
were compared during the model-building process using 
the −2 log-likelihood statistics and the final model fit 
was assessed using PROC LOGISTIC with the Hosmer-
Lemeshow goodness-of-fit test.
Noninferiority analysis of the effect of treatment on 
risk for a bacteriological cure was completed by con-
structing a figure containing the confidence intervals 
for the treatment relative to both null (reference treat-
ments, QT, and SP) and the margins of equivalence 
(Piaggio et al., 2006).
Cox proportional hazards regression (PROC 
PHREG) was used to describe the effect of DCT treat-
ment on the survival distribution function of quarters 
experiencing a case of clinical mastitis between calving 
and 100 DIM (note: no clinical mastitis events were 
reported by the farm personnel during the dry period). 
Quarters were considered to be at risk between calving 
and 100 DIM, with the failure date defined as the date 
when the quarter was first reported to be affected by a 
clinical mastitis event. Quarters not reported to experi-
ence a clinical mastitis event were classified as censored 
either at the cow’s culling or death date (if before 100 
DIM) or at 100 DIM. Clustering at the herd level was 
controlled for with a COVSANDWICH statement. Co-
variates offered to the model included DCT treatment 
group (forced), region (forced), cow parity, previous 
lactation LS, previous lactation total milk production 
(kg), dry period length (days), teat end score at dry-
off, and udder hygiene score at dry-off. Models were 
compared during the model-building process using the 
−2 log-likelihood statistics and the final model fit was 
assessed plotting the deviance residuals.
RESULTS
A total of 4,364 quarters (1,091 cows) were enrolled 
in the study between February and April of 2011. Of 
those, 1,492, 1,396, and 1,476 quarters were allocated 
to treatment groups QT, SP, and TM, respectively. The 
treatment groups did not differ at enrollment regard-
ing the following cow-level parameters (overall mean ± 
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SD): parity (2.9 ± 1.2), previous LS (3.0 ± 1.6), previ-
ous total milk (12,551 ± 3,392 kg), dry period length 
(54.2 ± 11.5 d), and udder hygiene score (1.7 ± 0.7) 
at dry-off. At the quarter level, treatment groups did 
not differ regarding teat end scores (1.7 ± 0.8) at dry-
off. Missing information included 11 cows with missing 
previous LS and previous total milk (QT: n = 7, SP: n 
= 2, and TM: n = 2), 27 cows with missing dry period 
lengths (QT: n = 10, SP: n = 10, and TM: n = 7) and 
15 quarters with missing teat end scores (QT: n = 9, 
SP: n = 0, and TM: n = 6). Previous total milk was 
excluded for 1 cow due to an unrealistic reported value 
of 117 kg.
IMI Status at Dry-Off
A total of 4,260 quarters were used for analysis of risk 
for presence of infection at dry-off, due to 13 missed 
samples (QT: n = 5, SP: n = 5, and TM: n = 3) and 
91 contaminated samples (QT: n = 28, SP: n = 33: 
and TM: n = 30). The overall crude prevalence of IMI 
at dry-off was 19.2% (Table 2) and was not different 
among treatments [LSM: QT = 0.22 (95% CI: 0.18, 
0.26), SP = 0.21 (95% CI: 0.18, 0.26), and TM = 0.23 
(95% CI: 0.19, 0.27); P = 0.73]. Significant covariates 
in the model predicting presence of IMI at dry-off in-
cluded region (P < 0.01), previous LS (P < 0.01), teat 
end score at dry-off (P < 0.01), udder hygiene score at 
dry-off (P = 0.04), and parity (P < 0.01; model not 
shown). The pathogen most commonly isolated from 
milk samples at dry off was CNS, representing 53.9% 
of all isolates recovered, followed by Aerococcus spp. 
(12.3%) and Streptococcus spp. (7.4%). Gram-positive 
organisms, gram-negatives and “others” represented 
94.4, 4.9, and 0.7% of all organisms isolated, respec-
tively (Table 3).
Effect of Treatment on Risk for Presence  
of an IMI at 0 to 6 DIM (S2)
A total of 4,058 quarters were used in the analysis of 
risk for presence of infection at 0 to 6 DIM (S2). From 
the 4,364 quarters initially enrolled, 108 quarters (27 
cows) were from cows that either were culled or died 
during the dry period (QT: n = 40, SP: n = 40, and 
TM: n = 28), 99 quarters were from cows that did not 
have their first postcalving sample collected (QT: n = 
20, SP: n = 47, and TM: n = 32), 16 quarters were from 
cows that died between calving and their first postcalv-
ing sample (QT: n = 4, SP: n = 4, and TM: n = 8), 
8 quarters were from cows that were culled between 
calving and their first postcalving sample (QT: n = 4, 
SP: n = 4, and TM: n = 0) and 75 samples were con-
taminated (QT: n = 26, SP: n = 27, and TM: n = 22).
The overall crude proportion of quarters with an IMI 
present at S2 (0 to 6 DIM) was 14.7% (Table 2), with 
no difference among the 3 treatments [LSM: QT = 0.16 
(95% CI: 0.14, 0.19), SP = 0.14 (95% CI: 0.12, 0.17), 
and TM = 0.16 (95% CI: 0.14, 0.19); P = 0.34]. In ad-
dition to treatment, the variables describing region (P 
< 0.01), previous LS (P < 0.01), and teat end score at 
dry-off (P = 0.01) were kept in the final model (Table 
4).
The most common pathogen isolated at the first sam-
pling postcalving (S2) was CNS (44.6% of all isolates 
recovered), followed by Aerococcus spp. (15.5%) and 
Bacillus spp. (10.0%). Gram-positives, gram-negatives, 
and “others” represented 89.7, 7.0, and 3.3% of all 
pathogens recovered, respectively (Table 3). Despite 
the fact that a priori sample size calculations were not 
completed to allow for subgroup analysis, the effect of 
treatment on prevalence of an IMI postcalving was also 
modeled separately for presence of IMI caused by gram-
Table 2. Crude prevalence (no., with percentages in parentheses) of intramammary infections for quarters at dry-off and 0 to 6 d in milk by 
treatment group and overall1 
Item
IMI present at dry-off IMI present at 0 to 6 DIM
QT SP TM Total QT SP TM Total
No growth 1,180 1,105 1,140 3,425 1,179 1,100 1,170 3,449
(79.4) (79.4) (77.4) (78.7) (82.8) (84.6) (83.1) (83.5)
Total IMI 279 253 305 835 219 174 216 609
(18.8) (18.2) (20.7) (19.2) (15.4) (13.4) (15.3) (14.7)
Single IMI 256 226 275 753 189 146 194 529
(17.2) (16.5) (18.7) (17.3) (13.3) (11.2) (13.8) (12.8)
Mixed IMI 23 27 30 82 30 28 22 80
(1.6) (1.9) (2.0) (1.9) (2.1) (2.1) (1.6) (1.9)
Contaminated 28 33 30 91 26 27 22 75
(1.9) (2.4) (2.0) (2.1) (1.8) (2.1) (1.6) (1.8)
Total quarters 1,487 1,391 1,473 4,351 1,424 1,301 1,408 4,133
1QT = Quartermaster (1,000,000 IU of procaine penicillin G and 1 g of dihydrostreptomycin; Pfizer Animal Health, New York, NY); SP = 
Spectramast DC (500 mg of ceftiofur hydrochloride; Pfizer Animal Health); TM = ToMorrow Dry Cow (300 mg of cephapirin benzathine; 
Boehringer Ingelheim Vetmedica Inc., St. Joseph, MO).
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positive or gram-negative organisms. These analyses 
showed no effect of treatment on risk for presence of 
gram-positive IMI or risk for presence of gram-negative 
IMI (models not shown).
Effect of Treatment on Risk for Experiencing  
a Cure Between Dry-Off and Postcalving
A total of 835 quarters had an IMI present at dry-off 
and so were at risk for a cure. However, quarters for 
which samples were contaminated or missing for any 
1 of the 2 samples postcalving (S2 or S3) could not be 
assigned a cure status and, therefore, were not included 
in the analysis. Out of the initially eligible quarters, 
a total of 11 samples were contaminated (QT: n = 5, 
SP: n = 2, and TM: n = 4) and 41 missing samples 
(QT: n = 10, SP: n = 17, and TM: n = 14) for samples 
collected at 0 to 6 DIM, and 15 contaminated samples 
(QT: n = 8, SP: n = 5, and TM: n = 2) and 27 missing 
samples (QT: n = 11, SP: n = 12, and TM: n = 4) 
for samples collected at 7 to 13 DIM. Therefore, 741 
quarters were included in the final analysis. Overall, 
the crude proportion of quarters experiencing a cure 
between dry-off and postcalving was 88.9% (Table 5), 
with no difference among the 3 treatment groups [LSM: 
QT = 0.93 (95% CI: 0.87, 0.97), SP = 0.93 (95% CI: 
0.86, 0.96), and TM = 0.94 (95% CI: 0.89, 0.97); P = 
0.79]. Teat end score at dry-off (P < 0.01) and teat end 
score at S3 (P = 0.04) were associated with risk for cure 
(Table 6). Although this final model defined cure as the 
Table 3. Description and frequency (no., with percentages in parentheses) of bacterial species for quarters that had an infection present at 
dry-off and at 0 to 6 DIM1 
Item
IMI present at dry-off IMI present at 0 to 6 DIM
QT SP TM Total QT SP TM Total
Bacteria
 Gram-positive
  Aerococcus spp. 33 40 40 113 45 29 33 107
(10.9) (14.3) (11.9) (12.3) (18.1) (14.4) (13.9) (15.5)
  Bacillus spp. 21 25 17 63 31 23 15 69
(7.0) (8.9) (5.1) (6.9) (12.4) (11.4) (6.3) (10.0)
  CNS 175 135 184 494 108 94 105 307
(57.9) (48.2) (54.9) (53.9) (43.4) (46.5) (44.1) (44.6)
  Corynebacterium spp. 20 18 26 64 6 7 9 22
(6.6) (6.4) (7.8) (7.0) (2.4) (3.5) (3.8) (3.2)
  Enterococcus spp. 4 8 6 18 9 6 5 20
(1.3) (2.9) (1.8) (2.0) (3.6) (3.0) (2.1) (2.9)
  Other gram-positive 1 4 3 8 0 1 6 7
(0.3) (1.4) (0.9) (0.9) (0.0) (0.5) (2.5) (1.0)
  Other Streptococcus spp. 19 23 26 68 18 13 23 54
(6.3) (8.2) (7.8) (7.4) (7.2) (6.4) (9.7) (7.8)
  Staphylococcus aureus 5 9 9 23 4 4 1 9
(1.7) (3.2) (2.7) (2.5) (1.6) (2.0) (0.4) (1.3)
  Streptococcus dysgalactiae 1 6 4 11 2 6 6 14
(0.3) (2.1) (1.2) (1.2) (0.8) (3.0) (2.5) (2.0)
  Streptococcus uberis 2 0 2 4 3 3 3 9
(0.7) (0.0) (0.6) (0.4) (1.2) (1.5) (1.3) (1.3)
  Total gram positives 281 268 317 866 226 186 206 618
(93.0) (95.7) (94.6) (94.4) (90.8) (92.1) (86.6) (89.7)
 Gram-negative
  Escherichia coli 2 1 2 5 9 7 3 19
(0.7) (0.4) (0.6) (0.5) (3.6) (3.5) (1.3) (2.8)
  Enterobacter spp. 1 0 4 5 0 0 2 2
(0.3) (0.0) (1.2) (0.5) (0.0) (0.0) (0.8) (0.3)
  Klebsiella spp. 5 1 5 11 0 1 1 2
(1.7) (0.4) (1.5) (1.2) (0.0) (0.5) (0.4) (0.3)
  Other gram-negative 7 5 3 15 7 5 9 21
(2.3) (1.8) (0.9) (1.6) (2.8) (2.5) (3.8) (3.0)
  Serratia spp. 3 3 3 9 1 0 3 4
(1.0) (1.1) (0.9) (1.0) (0.4) (0.0) (1.3) (0.6)
  Total gram negatives 18 10 17 45 17 13 18 48
(6.0) (3.6) (5.1) (4.9) (6.8) (6.4) (7.6) (7.0)
Other organisms (yeast) 3 2 1 6 6 3 14 23
(1.0) (0.7) (0.3) (0.7) (2.4) (1.5) (5.9) (3.3)
Total 302 280 335 917 249 202 238 689
1QT = Quartermaster (1,000,000 IU of procaine penicillin G and 1 g of dihydrostreptomycin; Pfizer Animal Health, New York, NY); SP = 
Spectramast DC (500 mg of ceftiofur hydrochloride; Pfizer Animal Health); TM = ToMorrow Dry Cow (300 mg of cephapirin benzathine; 
Boehringer Ingelheim Vetmedica Inc., St. Joseph, MO). 
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failure to culture bacterial pathogens in both samples 
postcalving, separate models that defined cure as the 
failure to culture a bacterial pathogen between dry-off 
and either the first or the second sampling postcalving 
found similar results (models not shown).
The effect of treatment on this primary outcome was 
also evaluated using noninferiority analysis by con-
structing a figure containing the confidence interval for 
the treatment effect and both the margins of inferiority 
and the null effect (Piaggio et al., 2006). Because the 
Table 4. Final multivariate logistic regression model for the analysis of odds for presence of an IMI at 0 to 
6 DIM 
Variable1 Coefficient SE
Odds 
ratio2
95% CI3
P-valueLCL UCL
Intercept −1.67 0.18
Treatment
 QT 0.04 0.12 1.04 0.81 1.32 0.34
 SP −0.15 0.13 0.86 0.67 1.12
 TM Referent 1.00
Region
 CA −0.46 0.12 0.63 0.50 0.81 <0.01
 IA −0.21 0.13 0.81 0.63 1.05
 MN Referent 1.00
Teat score at S14
 1 and 2 −0.33 0.13 0.72 0.56 0.93 0.01
 3 and 4 Referent 1.00
Previous LS5 0.14 0.03 1.15 1.08 1.22 <0.01
1QT = Quartermaster (1,000,000 IU of procaine penicillin G and 1 g of dihydrostreptomycin; Pfizer Animal 
Health, New York, NY); SP = Spectramast DC (500 mg of ceftiofur hydrochloride; Pfizer Animal Health); TM 
= ToMorrow Dry Cow (300 mg of cephapirin benzathine; Boehringer Ingelheim Vetmedica Inc., St. Joseph, 
MO); CA = California; IA = Iowa; MN = herds from both states of Minnesota and Wisconsin.
2Odds for presence of an IMI.
3Confidence interval for the odds ratio: lower (LCL) and upper (UCL) confidence limits.
4Sample 1 (S1) corresponds to the dry-off event.
5Last linear score (LS) before dry-off.
Table 5. Crude quarter-level bacteriological cures by pathogen group 
Item
Cure1
QT SP TM Total
Quarters at risk for a cure (no.) 243 217 281 741
Quarters experiencing a cure [% (no.)] 88.9 (216) 88.0 (191) 89.7 (252) 88.9 (659)
Gram-positive2 [% (no.)]
 Aerococcus spp. 93.3 (30) 88.9 (36) 97.4 (39) 93.3 (105)
 Bacillus spp. 94.7 (19) 87.0 (23) 88.2 (17) 89.8 (59)
 CNS 81.7 (153) 82.0 (111) 84.5 (168) 82.9 (432)
 Corynebacterium spp. 100.0 (13) 100.0 (18) 100.0 (24) 100.0 (55)
 Enterococcus spp. 100.0 (4) 100.0 (8) 100.0 (5) 100.0 (17)
 Other gram-positive 100.0 (1) 100.0 (4) 100.0 (3) 100.0 (8)
 Other Streptococcus spp. 100.0 (16) 84.2 (19) 77.3 (22) 86.0 (57)
 Staphylococcus aureus 80.0 (5) 42.9 (7) 88.9 (9) 71.4 (21)
 Streptococcus dysgalactiae — 60.0 (5) 75.0 (4) 66.7 (9)
 Streptococcus uberis 100.0 (1) — 100.0 (2) 100.0 (3)
Gram-negative2 [% (no.)]
 Escherichia coli 100.0 (2) 100.0 (1) 100.0 (1) 100.0 (4)
 Enterobacter spp. 100.0 (1) — 100.0 (4) 100.0 (5)
 Klebsiella spp. 100.0 (5) — 80.0 (5) 90.0 (10)
 Other gram-negative 100.0 (7) 100.0 (5) 66.7 (3) 93.3 (14)
 Serratia spp. 100.0 (2) 33.3 (3) 66.7 (3) 62.5 (8)
Others2 [% (no.)] 100.0 (2) 100.0 (1) 0.0 (1) 75.0 (4)
1QT = Quartermaster (1,000,000 IU of procaine penicillin G and 1 g of dihydrostreptomycin; Pfizer Animal 
Health, New York, NY); SP = Spectramast DC (500 mg of ceftiofur hydrochloride; Pfizer Animal Health); TM 
= ToMorrow Dry Cow (300 mg of cephapirin benzathine; Boehringer Ingelheim Vetmedica Inc., St. Joseph, 
MO).
2The percentage corresponds to the percentage of quarters experiencing a cure; the number is the number of 
quarters at risk for each category.
Journal of Dairy Science Vol. 96 No. 7, 2013
RANDOMIZED STUDY COMPARING DRY COW THERAPIES 4427
confidence interval for TM is wholly between the mar-
gins of inferiority and includes zero, we confirm that 
treatment with TM is noninferior to both treatments 
with QT and SP (Figures 1 and 2).
Despite the fact that a priori sample size calculations 
were not completed to allow for subgroup analysis, the 
effect of treatment on cure of an IMI was also modeled 
separately for cure of IMI caused by gram-positive or 
gram-negative organisms, and these analyses showed no 
effect of treatment on risk for cure of a gram-positive 
IMI or risk for cure of a gram-negative IMI (models 
not shown). It is important to mention that the small 
sample size for analysis of cure of an IMI caused by 
gram-negative pathogens does not allow for conclusions.
Effect of Treatment on Risk for Developing  
an NIMI Between Dry-Off and 0 to 6 DIM (S2)
All quarters enrolled were considered at risk for devel-
oping an NIMI over the dry period. However, quarters 
that had contaminated or missing samples at dry-off 
(S1) or at the first sampling postcalving (S2) were not 
assigned a new infection status and were, therefore, 
excluded from analysis. A total of 3,962 quarters were 
used for analysis of effect of treatment on new infec-
tions. A total of 402 quarters were not eligible for the 
analysis. Of these, 165 quarters were excluded due to 
contaminated samples (QT: n = 55, SP: n = 60, and 
TM: n = 50) and 237 quarters were excluded due to 
missing samples (QT: n = 71, SP: n = 97, and TM: n 
= 69).
The overall crude proportion of eligible quarters de-
veloping an NIMI between dry-off and 0 to 6 DIM was 
13.3% (Table 7). No effect was observed of treatment 
on risk for developing an NIMI [LSM: QT = 0.15 (95% 
CI: 0.12, 0.18), SP = 0.12 (95% CI: 0.10, 0.15), and TM 
= 0.14 (95% CI: 0.12, 0.17); P = 0.27]. Region (P < 
0.01), previous LS (P = 0.02), teat end score at dry-off 
(P = 0.02), and parity (P = 0.03) were associated with 
risk for developing an NIMI between dry-off and 0 to 
6 DIM (Table 8). The effect of treatment on risk for 
developing an NIMI between dry-off and 7 to 13 DIM 
was also modeled separately and showed no difference 
among the 3 treatments (model not shown). Despite 
the fact that a priori sample size calculations were not 
completed to allow for subgroup analysis, the effect of 
treatment on risk for NIMI was also modeled separately 
for NIMI caused by gram-positive or NIMI caused by 
gram-negative organisms and these analyses showed no 
effect of treatment on risk for a gram-positive NIMI 
or risk for a gram-negative NIMI (models not shown). 
It is important to note that the small sample size for 
analysis of NIMI caused by gram-negative pathogens 
does not allow for conclusions.
Table 6. Final multivariable logistic regression model for the analysis of odds for experiencing a cure between 
dry-off and calving 
Variable1 Coefficient SE
Odds 
ratio2
95% CI3
P-valueLCL UCL
Intercept 3.62 0.66
Treatment
 QT −0.10 0.30 0.90 0.50 1.63 0.79
 SP −0.21 0.31 0.81 0.44 1.47
 TM Referent 1.00
Region
 CA −0.41 0.28 0.67 0.38 1.16 0.30
 IA −0.41 0.35 0.66 0.33 1.31
 MN Referent 1.00
Teat score at S14
 1 and 2 −1.87 0.61 0.15 0.05 0.51 <0.01
 3 and 4 Referent 1.00
Teat score at S35
 1 and 2 0.65 0.32 1.92 1.03 3.60 0.04
 3 and 4 Referent  1.00
1QT = Quartermaster (1,000,000 IU of procaine penicillin G and 1 g of dihydrostreptomycin; Pfizer Animal 
Health, New York, NY); SP = Spectramast DC (500 mg of ceftiofur hydrochloride; Pfizer Animal Health); TM 
= ToMorrow Dry Cow (300 mg of cephapirin benzathine; Boehringer Ingelheim Vetmedica Inc., St. Joseph, 
MO); CA = California; IA = Iowa; MN = herds from both states of Minnesota and Wisconsin.
2Odds of experiencing a cure.
3Confidence interval for the odds ratio: lower (LCL) and upper (UCL) confidence limits.
4Sample 1 (S1) corresponds to the dry-off event.
5Sample 3 (S3) corresponds to the postcalving sampling collected between 7 and 13 DIM. 
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Effect of Treatment on Risk for Experiencing a 
Clinical Mastitis Event Between Calving and 100 DIM
For the survival analysis using the Cox proportional 
hazards regression model, 4,232 quarters were used, 
with a total of 24 quarters excluded from analysis 
due to missing previous LS information (QT: n = 
12, SP: n = 4, and TM: n = 8). Overall, 4.4% of the 
quarters experienced a clinical mastitis event from 
calving to 100 DIM. This analysis showed no effect of 
treatment on risk or days to a clinical mastitis event 
by 100 DIM (crude proportions: QT = 5.3%, SP = 
3.8%, and TM = 4.1%: P = 0.27). Other covariates 
significant in the multivariate model included region 
(P < 0.01), previous LS (P < 0.01), and parity (P = 
0.03: Table 9).
Figure 1. Noninferiority analysis of risk for cure for quarters from cows treated with ToMorrow Dry Cow (TM; Boehringer Ingelheim 
Vetmedica Inc., St. Joseph, MO; LSM = 0.94; 95% CI: 0.89 to 0.97) compared with cows treated with Quartermaster (QT; Pfizer Animal Health, 
New York, NY; LSM = 0.93; 95% CI: 0.87 to 0.97). The error bars indicate 2-sided 95% confidence intervals and the shaded area indicates the 
zone of noninferiority. Delta (Δ) represents the margin of noninferiority, preestablished at 10%.
Figure 2. Noninferiority analysis of risk for cure for quarters from cows treated with ToMorrow Dry Cow (TM; Boehringer Ingelheim 
Vetmedica Inc., St. Joseph, MO; LSM = 0.94; 95% CI: 0.89 to 0.97) compared with cows treated with Spectramast DC (SP; Pfizer Animal 
Health, New York, NY; LSM = 0.93; 95% CI: 0.86 to 0.96). The error bars indicate 2-sided 95% confidence intervals and the shaded area indi-
cates the zone of noninferiority. Delta (Δ) represents the margin of noninferiority, preestablished at 10%.
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Table 7. Crude quarter-level risk for new infections between dry-off and 0 to 6 DIM 
Item
New infection1
QT SP TM Total
Quarters at risk for the event (no.) 1,366 1,239 1,357 3,962
Quarters with a new IMI [% (no.)] 14.1 (192) 11.9 (148) 13.8 (187) 13.3 (527)
Gram-positive2 [% (no.)]
 Aerococcus spp. 2.8 (1,334) 2.9 (1,201) 2.4 (1,318) 2.7 (3,853)
 Bacillus spp. 1.3 (1,346) 0.8 (1,215) 0.5 (1,340) 0.9 (3,901)
 CNS 7.2 (1,201) 7.8 (1,115) 6.8 (1,185) 7.2 (3,501)
 Corynebacterium spp. 0.7 (1,349) 0.8 (1,221) 1.1 (1,332) 0.8 (3,902)
 Enterococcus spp. 0.4 (1,362) 0.2 (1,231) 0.2 (1,352) 0.3 (3,945)
 Other gram-positive 0.1 (1,365) 0.2 (1,235) 0.2 (1,354) 0.2 (3,954)
 Other Streptococcus spp. 1.7 (1,348) 1.5 (1,226) 1.2 (1,339) 1.5 (3,913)
 Staphylococcus aureus 0.1 (1,361) 0.2 (1,232) 0.1 (1,348) 0.1 (3,941)
 Streptococcus dysgalactiae 0.2 (1,366) 0.3 (1,234) 0.2 (1,353) 0.3 (3,953)
 Streptococcus uberis 0.3 (1,365) 0.3 (1,239) 0.3 (1,355) 0.3 (3,959)
Gram-negative2 [% (no.)]
 Escherichia coli 0.4 (1,364) 0.2 (1,238) 0.4 (1,356) 0.4 (3,958)
 Enterobacter spp. 0.0 (1,365) 0.0 (1,239) 0.0 (1,353) 0.0 (3,957)
 Klebsiella spp. 0.0 (1,364) 0.0 (1,236) 0.1 (1,352) 0.0 (3,952)
 Other gram-negative 0.4 (1,364) 0.5 (1,236) 0.4 (1,355) 0.5 (3,955)
 Serratia spp. 0.1 (1,363) 0.2 (1,236) 0.1 (1,354) 0.1 (3,953)
Other organisms2 [% (no.)] 0.5 (1,365) 0.2 (1,237) 0.4 (1,356) 0.4 (3,958)
1QT = Quartermaster (1,000,000 IU of procaine penicillin G and 1 g of dihydrostreptomycin; Pfizer Animal 
Health, New York, NY); SP = Spectramast DC (500 mg of ceftiofur hydrochloride; Pfizer Animal Health); TM 
= ToMorrow Dry Cow (300 mg of cephapirin benzathine; Boehringer Ingelheim Vetmedica Inc., St. Joseph, 
MO).
2The percentage is the percentage of quarters developing a new IMI and the number is the number of quarters 
at risk of acquiring a new IMI for each pathogen, excluding quarters that already had the specific pathogen 
present at dry-off.
Table 8. Final multivariable logistic regression model for the analysis of effect of treatment on odds for 
acquiring a new IMI between dry-off and 0 to 6 DIM 
Variable1 Coefficient SE
Odds 
ratio2
95% CI3
P-valueLCL UCL
Intercept −1.46 0.21
Treatment
 QT 0.05 0.13 1.05 0.81 1.35 0.27
 SP −0.17 0.13 0.85 0.65 1.11
 TM Referent 1.00
Region
 CA −0.65 0.13 0.52 0.41 0.68 <0.01
 IA −0.25 0.13 0.78 0.60 1.01
 MN Referent 1.00
Parity
 2 −0.25 0.12 0.78 0.62 0.98 0.03
 >2 Referent 1.00
Teat score at S14
 1 and 2 −0.31 0.14 0.73 0.56 0.96 0.02
 3 and 4 Referent 1.00
Previous LS5 0.08 0.04 1.09 1.01 1.17 0.02
1QT = Quartermaster (1,000,000 IU of procaine penicillin G and 1 g of dihydrostreptomycin; Pfizer Animal 
Health, New York, NY); SP = Spectramast DC (500 mg of ceftiofur hydrochloride; Pfizer Animal Health); TM 
= ToMorrow Dry Cow (300 mg of cephapirin benzathine; Boehringer Ingelheim Vetmedica Inc., St. Joseph, 
MO); CA = California; IA = Iowa; MN = herds from both states of Minnesota and Wisconsin.
2Odds of acquiring a new infection.
3Confidence interval for the odds ratio: lower (LCL) and upper (UCL) confidence limits.
4Sample 1 (S1) corresponds to the dry-off event.
5Last linear score (LS) before dry-off.
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Out of the total numbers of quarters that experi-
enced a clinical case from calving to 100 DIM, 51.6% 
of the milk samples were missing (i.e., not collected 
by herd staff), 23.1% yielded no growth, 2.7% corre-
sponded to mixed infections, and 1.6% corresponded to 
contaminated samples. Of the milk samples for which 
bacteria were isolated, the majority of IMI were caused 
by Escherichia coli (22.4%), followed by Strep. uberis 
(12.2%), and other Streptococcus spp. (12.2%).
DISCUSSION
The current study found that TM was noninferior in 
effecting the primary outcome of bacteriological cure 
compared with QT or SP. The study also found no 
difference in efficacy between the 3 DCT treatments 
when evaluated at the quarter level for risk for presence 
of IMI at 0 to 6 DIM, risk for development of NIMI 
between dry-off and 0 to 6 DIM, and risk for a clinical 
mastitis event between calving and 100 DIM.
This is the first prospective multi-state, multi-herd 
noninferiority North American study specifically de-
signed to compare efficacy among 3 commonly used 
commercial DCT products. It is difficult to compare 
results from this study to previous research because 
peer-reviewed publications directly comparing those 3 
or any other DCT products are almost entirely lack-
ing. A randomized trial conducted in 2006 evaluated 
the efficacy of both cephapirin benzathine and ceftiofur 
hydrochloride to treat existing IMI and prevent NIMI 
during the dry period (Hallberg et al., 2006). However, 
the latter study was designed to compare these anti-
microbial treatments against a negative control group, 
and not each other, and so lacked a sufficient sample 
size to compare outcomes between the 2 antimicrobials 
tested. Furthermore, that study enrolled only cows with 
a SCC >400,000 cells/mL, which is not necessarily rep-
resentative of the target population, considering that 
most dairy producers in North America apply DCT to 
all cows at dry-off. A noninferiority study was recently 
conducted in New Zealand with the aim of comparing 
the efficacy of 2 cephalonium products (McDougall, 
2010). However, because that study had geographical 
differences and used different drug formulations, it does 
not allow for comparison with the present US study. 
A study conducted in Florida (Pinedo et al., 2012) 
compared SP and QT but did not report quarter-level 
outcomes, so comparisons cannot be made with the 
current study.
A strength of the present study is that it was con-
ducted in commercial dairy herds from 4 different 
states, using different dry cow housing and management 
strategies. Also, the types and frequencies of pathogens 
recovered were very similar to those reported in other 
North American dry cow mastitis studies. However, it 
must be acknowledged that the herds used in this study 
were larger than average (2,230 lactating cows), com-
pared with the average number of lactating cows in US 
dairy herds (167 lactating cows; USDA-NAHMS, 2010) 
and compared with herds that are enrolled in Min-
Table 9. Final Cox proportional hazards regression model for the analysis of effect of treatment on risk for 
experiencing a clinical mastitis event between calving and 100 DIM 
Variable1 Coefficient SE
Hazards 
ratio2
95% CI3
P-valueLCL UCL
Treatment
 QT 0.27 0.21 1.31 0.87 1.947 0.27
 SP −0.05 0.21 0.95 0.63 1.44
 TM Referent  1.00
Region
 MN 1.13 0.20 3.10 2.09 4.60 <0.01
 IA −1.26 0.38 0.28 0.13 0.60
 CA Referent 1.00
Previous LS4 0.17 0.05 1.19 1.08 1.30 <0.01
Parity
 2 −0.39 0.18 0.68 0.48 0.96 0.03
 >2 Referent 1.00
1QT = Quartermaster (1,000,000 IU of procaine penicillin G and 1 g of dihydrostreptomycin; Pfizer Animal 
Health, New York, NY); SP = Spectramast DC (500 mg of ceftiofur hydrochloride; Pfizer Animal Health); TM 
= ToMorrow Dry Cow (300 mg of cephapirin benzathine; Boehringer Ingelheim Vetmedica Inc., St. Joseph, 
MO); CA = California; IA = Iowa; MN = herds from both states of Minnesota and Wisconsin.
2Hazard of experiencing a clinical mastitis event.
3Confidence interval for the odds ratio: lower (LCL) and upper (UCL) confidence limits.
4Last linear score (LS) before dry-off.
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nesota DHIA (129 lactating cows; Minnesota DHIA, 
2011). Study herds also had higher rolling herd average 
(RHA) and lower average SCC (RHA = 12,360 kg and 
SCC = 242,170 cells/mL) compared with Minnesota 
DHIA herds (RHA = 9,600 kg and SCC = 304,000 
cells/mL; Minnesota DHIA, 2011). Finally, all study 
herds were using an internal teat sealant (Orbeseal; 
Pfizer Animal Health) and some kind of commercial 
coliform mastitis vaccine at dry-off. The 2007 NAHMS 
study (USDA-NAHMS, 2008) reported that approxi-
mately 30% of all operations and approximately 49% 
of larger operations with ≥500 cows routinely use an 
internal teat sealant. Similarly, approximately 38% of 
all operations reported vaccinating for coliform mastitis 
(USDA-NAHMS, 2010). As such, although results are 
generalizable to herds similar to those used in the cur-
rent study, future studies could investigate if findings 
are similar in smaller herds and (or) herds not routinely 
using internal teat sealants at dry-off.
IMI Status at Dry-Off and Effect of Treatment  
on Risk for Presence of an IMI at 0 to 6 DIM (S2)
The current study found no effect of treatment on 
risk for presence of an IMI at dry-off or after calving. 
The crude prevalence of infection at dry-off reported in 
this study (19.2%) was within the range commonly re-
ported in other North American dry cow studies (God-
den et al., 2003; Hallberg et al., 2006; Pantoja et al., 
2009), even though some differences may be expected 
partly due to differences in IMI definitions or sampling 
methodology among studies. In a study of 2 Wisconsin 
dairies, a prevalence of IMI at dry-off of approximately 
32% was reported when an IMI was defined as the pres-
ence of 1 colony in 0.1 mL of milk for any pathogen 
(Godden et al., 2003), whereas 12.8% was reported in 
another study of 1 Wisconsin herd where the threshold 
of presence of 3 or more colonies in 0.01 mL of milk 
was required to define an IMI (Pantoja et al., 2009). 
Postcalving prevalence of IMI reported in recent dry 
cow mastitis studies is highly variable. Prevalence of in-
fection from 2 to 9 DIM for quarters from cows treated 
with penicillin/dihydrostreptomycin has been reported 
as 6.9% (Pantoja et al., 2009), whereas a different study 
reported a postcalving prevalence of IMI of 40.4% for 
quarters treated with ceftiofur hydrochloride and 44.5% 
for quarters treated with cephapirin benzathine (Hall-
berg et al., 2006). However, the latter study enrolled 
only high-somatic cell cows at dry-off, and so may have 
included more chronic infections. As such, one might 
expect quarters to be more likely to have subclinical 
infections present after calving. Postcalving prevalence 
of IMI in the current study (14.7%) is relatively similar 
to that reported by Godden et al. (2003), wherein IMI 
prevalence rates of 22.8 and 20.6% were reported at 1 
to 3 and 6 to 8 DIM, respectively.
Similar to previous dry cow mastitis studies, the 
pathogen most commonly isolated for all sampling 
events in the current study was CNS. Hallberg et al. 
(2006) reported that 62.6% of the pathogens isolated at 
dry-off were CNS, and Pantoja et al. (2009) reported 
that CNS was responsible for 63 and 44% of the in-
fections at dry-off and postcalving, respectively. The 
high frequency of environmental Streptococcus spp. 
found in the current study differs from some other dry 
cow studies, wherein lower frequencies were reported 
(Pantoja et al., 2009; Gundelach et al., 2011), but it is 
similar to what was reported by Godden et al. (2003). 
Interestingly, Bacillus spp. were isolated in pure culture 
consistently in dry-off and postcalving samples from 
all herds in all regions. The role of Bacillus spp. in 
subclinical IMI is not well established in the literature. 
Bacillus spp. are known to be incriminated as a cause of 
clinical mastitis (Nieminen et al., 2007) and are also re-
ported to be found in the normal bovine teat microflora 
(Al-Qumber and Tagg, 2006). We speculate that this 
pathogen might be considered a common contaminant 
by many microbiology laboratories and is, therefore, 
underreported in routine laboratory results. An alter-
native explanation may be that the prevalence of this 
organism may be increasing. The latter hypothesis may 
be supported by findings from a recent study wherein 
4% of clinical mastitis cases were caused by Bacillus 
spp. (Lago et al., 2011). Further research is required to 
investigate the relationship between Bacillus spp. and 
udder health and disease.
In the current study, relatively few gram-negative 
pathogens and very few contagious pathogens (Staph. 
aureus and Strep. agalactiae) were reported. Two pre-
vious studies reported the proportion of IMI caused 
by gram-negative pathogens in dry off samples to 
be approximately 0.25% (Pantoja et al., 2009), 1.5% 
(Hallberg et al., 2006), and 22% (Godden et al., 2003), 
whereas the proportion of IMI postcalving caused by 
gram-negative pathogens were reported as 0.86% (Pan-
toja et al., 2009) and 30% (Godden et al., 2003). Despite 
these highly variable rates of subclinical IMI, studies 
consistently report that the prevalence of subclinical 
coliform IMI during lactation is highest shortly after 
calving and tends to decrease as DIM advances (Hogan 
and Smith, 1998). The low number of Staph. aureus 
and Strep. agalactiae common to all study herds in the 
present study very likely reflects good overall mastitis-
control programs, including the implementation of the 
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Five-Point Program, a program developed at the Na-
tional Institute for Research in Dairying (Reading, UK) 
that was adopted by progressive herds to control and 
prevent IMI caused by contagious pathogens. Adoption 
of such methods has resulted in great progress over the 
years, and in this scenario other pathogens such as CNS 
and environmental Streptococcus spp. have become 
relatively more important. Another fact that might 
help to explain the low prevalence of Staph. aureus is 
the poor sensitivity to detect this pathogen in a single 
quarter milk sample (Sears et al., 1990). The current 
study did not report any Strep. agalactiae, which is 
similar to findings from other North American dry cow 
mastitis studies (Godden et al., 2003; Hallberg et al., 
2006; Pantoja et al., 2009).
Effect of Treatment on Risk for Experiencing  
a Cure Between Dry-Off and Postcalving
The current study found that TM was noninferior to 
QT or SP on risk for experiencing cure of an IMI dur-
ing the dry period. The crude proportion of quarters 
experiencing a cure in this study (88.9%) was similar to 
that reported in recent dry cow studies (Godden et al., 
2003; Pantoja et al., 2009; Gundelach et al., 2011). In a 
previous North American study evaluating ceftiofur hy-
drochloride and cephapirin benzathine, cure rates from 
dry-off to 3 and 5 DIM were lower than those reported 
in the present study (61.8 and 56.3 vs. 88.0 and 89.7% 
for ceftiofur and cephapirin, respectively). However, the 
latter study only enrolled cows with a high SCC, which 
may have represented more chronic infections and so 
might be less likely to cure (Hallberg et al., 2006).
One item that must be addressed is the fact that, 
because the crude IMI rate at dry-off was lower than 
anticipated (approximately 19% instead of the antici-
pated 30%), fewer infected quarters were enrolled at 
dry-off than originally anticipated. A post-hoc power 
calculation estimated that the study had approximately 
73% power to detect a difference (delta) of 10% in cure 
rates between treatment groups compared. Although 
this loss of power needs to be acknowledged, we do 
not consider this to be a serious weakness of the study, 
given that the numeric difference observed in cure rates 
was very small (observed delta <2%), and numerically 
in favor of the TM product (LSM estimates of cure 
rates: TM = 94.0%, QM = 93.3%, and SP = 92.6%) . 
Therefore, we do not believe that the loss of power in 
any way compromised the validity of the conclusions 
reached in this study. Had the observed delta in cure 
rates been hovering around the −10% mark, then the 
reduced power for this study would be a more serious 
limitation.
Effect of Treatment on Risk for Developing  
an NIMI Between Dry-Off and 0 to 6 DIM (S2)
The current study found no effect of treatment on 
risk for development of NIMI postcalving. The new 
crude IMI rate reported in the current study (13.3%) is 
within the range reported in other recent studies, which 
have reported that NIMI incidences vary between 6 to 
36% (Godden et al., 2003; Cook et al., 2005; Hallberg et 
al., 2006; Pantoja et al., 2009; Gundelach et al., 2011). 
The majority of NIMI were caused by CNS and en-
vironmental streptococci in the current study. Similar 
findings were reported by Godden et al. (2003) and 
Pantoja et al. (2009). However, the 2 latter studies had 
gram-negative pathogens among the 3 most common 
organisms causing NIMI, which was not observed in the 
current study.
Effect of Treatment on Risk for Experiencing a 
Clinical Mastitis Event Between Calving and 100 DIM
The crude incidence of clinical mastitis in early 
lactation in the current study (4.4%) matches the 
incidence rates reported in previous North American 
studies, which ranged between 3 to 6% (Godden et al., 
2003; Gundelach et al., 2011). We were not able to 
adequately characterize pathogens causing all of these 
cases because personnel from the study herds did not 
consistently collect and submit milk samples from clini-
cal cases.
Secondary Findings
Previous LS. The current study detected inter-
esting associations between other covariates and the 
dependent variables of interest. As an example, the 
previous LS from the last DHIA test day before dry-off 
was positively associated with risk for presence of an 
IMI at dry-off, at 0 to 6 DIM and with risk for a clini-
cal mastitis event between calving and 100 DIM. This 
is consistent with a previous study that reported that 
cows with a SCC ≥200,000 at dry-off and postcalving 
were 2.7 times more likely to experience a first case of 
mastitis in the first 120 DIM than quarters with SCC 
<200,000 cells/mL (Pantoja et al., 2009). In the cur-
rent study, a 1-unit increase in LS before drying off was 
associated with a 23% increased odds of developing a 
clinical case between calving and 100 DIM. Previous LS 
was also positively associated with risk for development 
of an NIMI between dry-off and postcalving, which has 
also been previously reported by several authors (God-
den et al., 2003; McDougall, 2010). Somatic cell count 
measure is commonly used as an indicator of udder 
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infection status, as it reflects the number of leukocytes 
moving from the bloodstream to the cow’s mammary 
gland to fight infection. Preexisting inflammation (high 
SCC) and potential subclinical infection might indi-
rectly characterize a quarter at greater risk for develop-
ment of NIMI or clinical flare-ups, especially during 
periods when the cow is immunosuppressed, such as 
during the transition time.
Teat End Score. Previous reports on the nature of 
the association between teat end score and risk for pres-
ence or incidence of IMI are somewhat contradictory, 
and the relationship between teat end score and cure 
risk has never been previously described in the litera-
ture. Some studies found that risk for IMI in quarters 
with normal teat ends was not different from quarters 
with chronic ring lesions on teat ends (Sieber and Farn-
sworth, 1981). However, findings from the current study 
are consistent with other studies reporting that worse 
teat end condition is positively associated with risk for 
presence of subclinical infections (de Pinho Manzi et 
al., 2012) and that rough or cracked teat ends are a 
risk factor for the development of NIMI during the dry 
period (Dingwell et al., 2004). Counterintuitively, quar-
ters with a teat end scored 1 or 2 at dry-off were 85% 
less likely to experience a cure compared with teat ends 
scored 3 or 4. We have no immediate explanation for 
this observed relationship. Quarters with teat ends that 
have lesions or that are keratinized could potentially be 
at a higher risk for development of NIMI due to the fact 
that pathogens may colonize these cracks and crevices, 
putting them in close proximity to the streak canal, 
and so predisposing the quarter to infection by ascend-
ing bacteria. It has been recently reported that teats 
with a calloused end and hyperkeratosis are character-
ized by a higher environmental microbial load (Paduch 
et al., 2012).
Udder Hygiene Score. Udder hygiene score at 
dry-off was positively associated with presence of an 
IMI at dry-off. This observation is in agreement with 
findings from a previous study wherein a positive as-
sociation was reported between subclinical mastitis and 
measurements of animal hygiene (Schreiner and Ruegg, 
2003). It has been proposed that udder and leg hygiene 
scores of cows provide evidence on the degree that teat 
ends are exposed to environmental mastitis pathogens, 
which is correlated to risk for presence of subclinical 
IMI (Schreiner and Ruegg, 2003).
Parity. The current study found that increasing 
parity was positively associated with risk for develop-
ment of NIMI during the dry period and also with risk 
for a clinical mastitis event between calving and 100 
DIM. Increasing parity has been previously reported as 
a risk factor for presence of IMI (Green et al., 2005), 
new infections (Dingwell et al., 2004; Cook et al., 2005; 
McDougall, 2010), and clinical cases until 120 DIM 
(Pantoja et al., 2009). Anatomical and intramammary 
defense mechanisms of cows may deteriorate with age, 
an example being the reduced function and increased 
diameter of the streak canal (Dingwell et al., 2004). 
Older cows are also more likely to have been previously 
exposed or infected with mastitis pathogens, which has 
been discussed as potential risk factor that can contrib-
ute to susceptibility for new infections (Pantoja et al., 
2009).
Summary
The current study found that TM was noninferior in 
effecting a bacteriological cure compared with SP or 
QT, and that no difference in efficacy existed between 
the 3 commercial DCT products tested when consider-
ing all other quarter-level outcomes examined. These 
results are consistent with the fact that all 3 DCT 
products evaluated are labeled to be effective against 
one or more gram-positive organisms, and the majority 
of IMI detected in the current study were caused by 
gram-positive organisms. None of the 3 DCT products 
evaluated are labeled against gram-negative organisms, 
even though they are all recognized to have varying de-
grees of gram-negative activity in in vitro tests (Salmon 
et al., 1996; Constable and Morin, 2002; Oliver and 
Murinda, 2012). However, gram-negative IMI made up 
relatively few IMI cases in the current study.
CONCLUSIONS
Results from this noninferiority study demonstrate 
that, in herds using blanket Orbeseal infusion at dry-
off, no difference in efficacy existed between the prod-
ucts QT, SP, and TM regarding risk for presence of 
IMI at 0 to 6 DIM, risk for experiencing a cure during 
the dry period, risk for developing an NIMI between 
dry-off and 0 to 6 DIM, and risk for experiencing a 
clinical mastitis event between calving and 100 DIM. 
Specifically, TM was noninferior in effecting a bacterio-
logical cure compared with QT or SP. As such, dairy 
producers could potentially put aside concerns about 
differences in product efficacy, and instead base their 
selection decision among these 3 products on other 
characteristics such as milk and meat withholding time, 
targeted dry period length, and cost. From the point of 
view of promoting the prudent use of antimicrobials, 
as QT (penicillin/dihydrostreptomycin) and TM (cep-
hapirin benzathine, a first-generation cephalosporin) 
products had similar efficacy compared with SP (ceft-
iofur hydrochloride, a third-generation cephalosporin), 
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the veterinary community might consider recommend-
ing the use of the older simpler antimicrobials as a first 
choice when recommending a DCT product.
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